- HOME >
- GRADUATE >
- Human Sciences >
Medicine (Neurology, Rheumatology, Clinical Immunology)
| Master's Program | Human Sciences, Graduate School of Medicine |
|---|---|
| Doctor's Program | Medical Science Division, Department of Medical Science, Graduate School of Medicine, Science and Technology |
| Professor | SEKIJIMA Yoshiki |
|---|---|
| Associate Professor | SHIMOJIMA Yasuhiro, KATO Nagaaki |
| Senior Assistant Professor | KODAIRA Minori, MIYAZAKI Daigo, HINENO Akiyo, NAKAMURA Katsuya, KISHIDA Dai |
| Assistant Professor | TAKASONE Ken, ICHIKAWA Takanori |
E-mail ： sannai(at)shinshu-u.ac.jp
※ Change (at) to @ when you send an e-mail.
Department of Medicine (Neurology and Rheumatology) is focusing on the development of skills to explore the patients' whole body.
In the Neurology area, our target is total nervous system of the whole body which consist of the brain, spine, peripheral nerve, and muscles. There are many neurological disorders which do not show any abnormality in blood tests or imaging examination. Therefore it is very important to make a correct diagnosis through the whole body physical examinations and neurological examinations.
In the Rheumatology area, we see the patients with connective tissue disorders which mainly involve the whole body joints. You might be able to get the ability to find abnormal joints by touching and feeling the patients' joints by your own hands.
Amyloidosis is a disorder characterized by the deposition of abnormal protein called 'amyloid' into the whole body, such as the brain, heart, kidney, liver, digestive tract, peripheral nervous system, muscles, and endocrine systems. These visceral organs are also involved among the patients with rheumatic diseases.
Therefore, you may get the specialized skills as an neurologist and rheumatologist and also get the general skills to see and manage the patients' whole body issue. See following pages to check the details of our research works.
Divisions:
1. Amyloidosis team
2. Brain Disease Research team
3. Muscular disorder team
4. Rheumatic disorder team
1. Shimojima Y, Ichikawa T, Kishida D, Takamatsu R, Sekijima Y. Circulating regulatory T cells in adult-onset Still’s disease: focusing on their plasticity and stability. Clin Exp Immunol 2021; 206: 184-195.
2. Takasone K, Katoh N, Takahashi Y, Abe R, Ezawa N, Yoshinaga T, Yanagisawa S, Yazaki M, Oguchi K, Koyama J, Sekijima Y. Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-Pittsburgh compound B PET imaging. Amyloid 2020; 27: 266-274.
3. Shimojima Y, Kishida D, Ueno KI, Ushiyama S, Ichikawa T, Sekijima Y. Characteristics of circulating natural killer cells and their interferon-γ production in active adult-onset Still disease. J Rheumatol 2019; 46: 1268-1276.
4. Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21.
5. Schonhoft JD, Monteiro C, Plate L, Eisele YS, Kelly JM, Boland D, Parker CG, Cravatt BF, Teruya S, Helmke S, Maurer M, Berk J, Sekijima Y, Novais M, Coelho T, Powers ET, Kelly JW. Peptide probes detect misfolded transthyretin oligomers in the plasma of hereditary amyloidosis patients. Sci Transl Med 2017; 9: eaam7621.
6. Sekijima Y, Yazaki M, Oguchi K, Ezawa N, Yoshinaga T, Yamada M, Yahikozawa H, Watanabe M, Kametani F, Ikeda SI. Cerebral amyloid angiopathy in post-transplant patients with hereditary ATTR amyloidosis. Neurology 2016; 87: 773-781.
7. Wen Z, Shimojima Y, Shirai T, Li Y, Ju J, Yang Z, Tian L, Goronzy JJ, Weyand CM. NADPH oxidase deficiency in aging CD8 regulatory T cells. J Clin Invest 2016; 126: 1953-67.
8. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 2015; 86:1036-1043.
9. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310: 2658-2667.
10. Sekijima Y, Wiseman LR, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, Kelly JW. The biological and chemical basis for tissue selective amyloid disease. Cell 2005; 121: 73-85.
